Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

12.51 +0.15 (+1.21%)

Official Closing Price Updated: 7:00 PM EST, Jan 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	606,904
Open	12.38
Bid (Size)	12.50 (200)
Ask (Size)	12.51 (200)
Prev. Close	12.36
Today's Range	12.15 - 12.60
52wk Range	4.020 - 13.41
Shares Outstanding	52,700,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

December 12, 2025

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

November 18, 2025

From Emergent BioSolutions

Via GlobeNewswire

Performance

YTD	N/A	N/A
1 Month	+7.8%	+7.8%
3 Month	+36.7%	+36.7%
6 Month	+89.0%	+89.0%
1 Year	+21.8%	+21.8%

More News

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

November 12, 2025

From Emergent BioSolutions

Via GlobeNewswire

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Emergent BioSolutions (EBS) Earnings Transcript ↗

October 30, 2025

Via The Motley Fool

These stocks are moving in today's session ↗

October 30, 2025

Via Chartmill

Here are the top movers in Thursday's session. ↗

October 30, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 30, 2025

Via Benzinga

The market is filled with gapping stocks in Thursday's session. ↗

October 30, 2025

Via Chartmill

Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗

October 30, 2025

Via Benzinga

Retail Traders Turn Ultra-Bullish On Emergent BioSolutions After Surprise Q3 Profit ↗

October 30, 2025

Via Stocktwits

What's going on in today's after hours session ↗

October 29, 2025

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 29, 2025

Via Benzinga

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

October 29, 2025

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

October 28, 2025

From Emergent BioSolutions

Via GlobeNewswire

Hancock Whitney's Enduring Dividend: A Beacon of Stability in Regional Banking

October 23, 2025

Via MarketMinute

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

October 08, 2025

From Emergent BioSolutions

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 02, 2025

Via Benzinga

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

September 24, 2025

From Emergent BioSolutions

Via GlobeNewswire

3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts ↗

September 24, 2025

Via MarketBeat

Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’ ↗

September 19, 2025

Via Stocktwits

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

September 19, 2025

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

September 15, 2025

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

September 09, 2025

From Emergent BioSolutions

Via GlobeNewswire

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

September 02, 2025

From Emergent BioSolutions

Via GlobeNewswire

Frequently Asked Questions

Is Emergent BioSolutions Inc. Common Stock publicly traded?

Yes, Emergent BioSolutions Inc. Common Stock is publicly traded.

What exchange does Emergent BioSolutions Inc. Common Stock trade on?

Emergent BioSolutions Inc. Common Stock trades on the New York Stock Exchange

What is the ticker symbol for Emergent BioSolutions Inc. Common Stock?

The ticker symbol for Emergent BioSolutions Inc. Common Stock is EBS on the New York Stock Exchange

What is the current price of Emergent BioSolutions Inc. Common Stock?

The current price of Emergent BioSolutions Inc. Common Stock is 12.51

When was Emergent BioSolutions Inc. Common Stock last traded?

The last trade of Emergent BioSolutions Inc. Common Stock was at 01/02/26 07:00 PM ET

What is the market capitalization of Emergent BioSolutions Inc. Common Stock?

The market capitalization of Emergent BioSolutions Inc. Common Stock is 659.28M

How many shares of Emergent BioSolutions Inc. Common Stock are outstanding?

Emergent BioSolutions Inc. Common Stock has 659M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.